Moolec Science SA

Moolec Science SA (MLEC) Stock Analysis

$0.850

0.000 (0.00%)At close

Loading chart…
High
0.850
Open
0.850
VWAP
—
Volume
0.00
Mkt Cap
40.57M
Low
0.850
Amount
0.00
EV/EBITDA, TTM
0.00

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed.

AI analysis of Moolec Science SA (MLEC)

Sell

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

Valuation Metrics

The current forward P/E ratio for Moolec Science SA (MLEC) is 0.00, compared to its 5-year average forward P/E of -6.20.

Forward P/E

Overvalued
5Y Average P/E
-6.20
Current P/E
0.00
Overvalued
-1.34
Undervalued
-11.06

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-6.44
Current EV/EBITDA
0.00
Overvalued
0.90
Undervalued
-13.78

Forward P/S

Fair
5Y Average P/S
9.15
Current P/S
0.07
Overvalued
25.82
Undervalued
-7.52

Alphio AI Price Scenarios for MLEC

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MLEC

$29.13

Scenario price

B

Base

Base · 50%MLEC

$22.46

Scenario price

B

Bear

Bear · 25%MLEC

$17.06

Scenario price

Events Timeline

2026-07-15 (ET)

10:30:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

2026-05-14 (ET)

09:20:00

Moolec Science Completes 2026 GLASO Commercial Planting Campaign

2026-04-29 (ET)

09:10:00

Moolec Science Completes First Phase of GLASO1 Industrialization

2026-04-07 (ET)

08:20:00

Moolec Science Successfully Expresses Bovine Myoglobin in Pea Seeds

2026-02-18 (ET)

09:40:00

Moolec Science SA Trading Halted Due to Volatility Trading Pause

News

MLEC FAQ — answered by Alphio AI

Moolec Science SA is a science-based food ingredient company. The Company operates an integrated platform encompassing research & development (R&D), manufacturing, and regulatory capabilities that span from molecular design to validation in both fermenter and field environments. It operates across the United States, Europe, and South America. The Company advances its molecular farming programs in crops such as soy and safflower to produce proteins and lipids with animal-like functionality and plant-based cost structures. It is developing a precision fermentation facility in Finland, under the SynBio Powerlabs brand, which will be dedicated to producing target proteins, enzymes, and other biomolecules using optimized microbial and cellular systems. Its product portfolio includes GLASO, PIGGY SOOY, VALORASOY, and MYCOFOOD. Its GLASO, a safflower-derived oil rich in functional lipids, is being used in formulations for small-animal feed. It operates in the Consumer Non-Cyclicals sector.

Moolec Science SA (MLEC) is not a good buy right now. The current price is $0.85, which is significantly down 79.47% year-to-date and 91.63% over the past year. The RSI is at an extremely low 10.62, indicating the stock is oversold, but this does not guarantee a rebound. The gross margin is negative at -17.81%, reflecting ongoing financial struggles. Additionally, the company's debt to equity ratio is alarmingly high at 789.74%, posing a serious risk to financial stability. While there was a recent surge in stock price due to a reverse stock split and increased shareholder interest, the overall performance and financial health suggest caution. The main risk is the high debt level, which could hinder recovery efforts and investor confidence.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading